NKTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NKTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 5.68 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Nektar Therapeutics's Beneish M-Score or its related term are showing as below:
During the past 13 years, the highest Beneish M-Score of Nektar Therapeutics was 16.52. The lowest was -4.30. And the median was -2.27.
The historical data trend for Nektar Therapeutics's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Beneish M-Score | Get a 7-Day Free Trial | 1.64 | -2.63 | -3.36 | -3.05 | -2.74 |
Nektar Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Beneish M-Score | Get a 7-Day Free Trial | -2.76 | -3.06 | -2.74 | 15.37 | 5.68 |
For the Biotechnology subindustry, Nektar Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Nektar Therapeutics for today is based on a combination of the following eight different indices:
M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
= | -4.84 | + | 0.92 * 0.7059 | + | 0.528 * 1.2025 | + | 0.404 * 20.6715 | + | 0.892 * 1.0617 | + | 0.115 * 0.8024 | |
- | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
- | 0.172 * 0.8933 | + | 4.679 * 0.094759 | - | 0.327 * 1.3622 | |||||||
= | 5.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun24) TTM: | Last Year (Jun23) TTM: |
Total Receivables was $2.90 Mil. Revenue was 23.489 + 21.639 + 23.885 + 24.144 = $93.16 Mil. Gross Profit was 13.749 + 13.105 + 16.602 + 11.713 = $55.17 Mil. Total Current Assets was $295.19 Mil. Total Assets was $343.33 Mil. Property, Plant and Equipment(Net PPE) was $24.43 Mil. Depreciation, Depletion and Amortization(DDA) was $6.41 Mil. Selling, General, & Admin. Expense(SGA) was $79.13 Mil. Total Current Liabilities was $57.33 Mil. Long-Term Debt & Capital Lease Obligation was $90.76 Mil. Net Income was -52.363 + -36.802 + -42.079 + -45.837 = $-177.08 Mil. Non Operating Income was -13.325 + -1.074 + -9.098 + -11.36 = $-34.86 Mil. Cash Flow from Operations was -37.702 + -47.888 + -47.047 + -42.121 = $-174.76 Mil. |
Total Receivables was $3.87 Mil. Revenue was 20.499 + 21.594 + 22.023 + 23.625 = $87.74 Mil. Gross Profit was 13.505 + 14.534 + 15.79 + 18.653 = $62.48 Mil. Total Current Assets was $441.06 Mil. Total Assets was $494.28 Mil. Property, Plant and Equipment(Net PPE) was $51.57 Mil. Depreciation, Depletion and Amortization(DDA) was $10.33 Mil. Selling, General, & Admin. Expense(SGA) was $83.42 Mil. Total Current Liabilities was $50.69 Mil. Long-Term Debt & Capital Lease Obligation was $105.82 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
= | (2.899 / 93.157) | / | (3.868 / 87.741) | |
= | 0.03112 | / | 0.044084 | |
= | 0.7059 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
= | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
= | (62.482 / 87.741) | / | (55.169 / 93.157) | |
= | 0.712119 | / | 0.592215 | |
= | 1.2025 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
= | (1 - (295.188 + 24.427) / 343.334) | / | (1 - (441.058 + 51.569) / 494.279) | |
= | 0.069084 | / | 0.003342 | |
= | 20.6715 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
SGI | = | Sales_t | / | Sales_t-1 |
= | Revenue_t | / | Revenue_t-1 | |
= | 93.157 | / | 87.741 | |
= | 1.0617 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
= | (10.327 / (10.327 + 51.569)) | / | (6.413 / (6.413 + 24.427)) | |
= | 0.166844 | / | 0.207944 | |
= | 0.8024 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
= | (79.126 / 93.157) | / | (83.423 / 87.741) | |
= | 0.849383 | / | 0.950787 | |
= | 0.8933 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
= | ((90.763 + 57.326) / 343.334) | / | ((105.817 + 50.694) / 494.279) | |
= | 0.431326 | / | 0.316645 | |
= | 1.3622 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
= | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
= | (-177.081 - -34.857 | - | -174.758) | / | 343.334 | |
= | 0.094759 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Nektar Therapeutics has a M-score of 5.68 signals that the company is likely to be a manipulator.
Thank you for viewing the detailed overview of Nektar Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Howard W Robin | director, officer: President & CEO | |
Jonathan Zalevsky | officer: Chief R&D Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Mark Andrew Wilson | officer: SVP & General Counsel | 1613 RAY DRIVE, BURLINGAME CA 94010 |
Robert Chess | director, officer: Executive Chairman | |
Myriam Curet | director | 1020 KIFER ROAD, SUNNYVALE CA 94086 |
Jeffrey Robert Ajer | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Sandra A. Gardiner | officer: Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jillian B. Thomsen | officer: VP & Chief Accounting Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Gil M Labrucherie | officer: SVP, COO & CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
John Northcott | officer: SVP & Chief Commercial Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Diana Brainard | director | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
R Scott Greer | director | 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253 |
Lutz Lingnau | director | 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945 |
Stephen K Doberstein | officer: Chief Scientific Officer | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
From GuruFocus
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 08-08-2024
By PRNewswire • 08-01-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 05-10-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By PRNewswire • 03-22-2024
By GuruFocus Research • 03-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.